Brief: Inhibikase Therapeutics Entered Into An At The Market Offering Agreement With H.C. Wainwright & Co As Sales Agent
01/02/2024 22:24
Feb 1 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS INC- ENTERED INTO AN AT THE
MARKET
OFFERING AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC, AS SALES
AGENT
* INHIBIKASE THERAPEUTICS-PURSUANT TO DEAL, CO MAY ISSUE &
SELL
SHARES OF ITS COMMON STOCK IN AN AGGREGATE OFFERING PRICE OF UP
TO $5.66 MILLION
Source text for Eikon: ID:n0001193125-24-021850
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share